Respiratory failure & ventilation
Convalescent Plasma for Covid-19–Induced Acute Respiratory Distress Syndrome (ARDS) in Mechanically Ventilated Patients
Authors' conclusion
The administration of plasma collected from convalescent donors with a neutralizing antibody titer of at least 1:160 to patients with Covid-19-induced ARDS within 5 days after the initiation of invasive mechanical ventilation significantly reduced mortality at day 28.
Study context
- Population
- Adults with Covid-19-induced ARDS receiving invasive mechanical ventilation for <5 daysSeptember 2020–March 2022
- Participants
- 475 adults
- Comparison
- Convalescent plasma vs standard care alone
- Convalescent plasman = 237
- Standard caren = 238reference
- Primary endpoint
- Death
- Follow-up
- Day 28
Methodological detailsopen-label, stratified randomisation by time from tracheal intubation to inclusion, Glucocorticoids administered to 466 patients (98.1%)
- Open-label
- Stratified randomisation by time from tracheal intubation to inclusion
- Glucocorticoids administered to 466 patients (98.1%)
Primary result
As reported in the abstract
Mortality
P = 0.03
Further findings
Mortality by time from initiation of invasive mechanical ventilation to randomisation (prespecified subgroup) · day 28
- Effect observed mainly in patients randomised ≤48 hours after initiation of invasive mechanical ventilation
- Prespecified analysis
Safety
Serious adverse events
- Did not differ substantially between the two groups
Original publication
Convalescent Plasma for Covid-19–Induced ARDS in Mechanically Ventilated Patients. N Engl J Med. Published 25 October 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →